Kapiva, India's leading modern Ayurveda brand, has raised $60 million in Series D funding to enhance its pioneering role in preventive healthcare through science-led Ayurvedic solutions.

Information on the Target

Kapiva, a prominent modern Ayurveda brand in India, has successfully secured $60 million in Series D funding from notable investors including 3one4 Capital, 360 ONE Asset, Vertex Growth Fund, and Vertex Ventures SE Asia & India. This funding signifies a pivotal step in Kapiva's mission to modernize preventive healthcare through scientifically-driven Ayurvedic solutions.

Since its inception, Kapiva has distinguished itself by combining traditional Ayurvedic practices with cutting-edge science, personalization, and seamless execution. The brand has evolved from a challenger in the wellness market to a transformative platform, utilizing clinical research and proprietary R&D to provide effective preventive healthcare products that address a variety of health needs such as diabetes management, hormonal balance, and overall wellness.

Industry Overview in India

The Ayurveda sector in India, traditionally dominated by established FMCG companies, is undergoing a significant transformation with the emergence of science-driven, results-oriented brands. With the rise in chronic health issues and a growing consumer preference for preventive care, the market is